SKLB-03220 is an orally bioavailable covalent inhibitor targeting the histone methyltransferase EZH2, an established oncology drug target involved in epigenetic regulation. SKLB-03220 is structurally based on the clinically approved EZH2 inhibitor tazemetostat and demonstrates the ability to abolish epigenetic H3K27me3 marks, thereby altering chromatin state and transcriptional activity. SKLB-03220 represents a potent small-molecule tool for cancer epigenetics research.
Molecular Weight:
556.71
Purity:
97.02%
CAS Number:
[2852050-29-2]
Formula:
C33H40N4O4
Target:
Histone Methyltransferase
T207811
* VAT and and shipping costs not included. Errors and price changes excepted
